Study Finds Gepotidacin Noninferior To Ceftriaxone Plus Azithromycin For Patients With Uncomplicated Urogenital Gonorrhea

HealthDay (4/21, Gotkine) reports on a study finding that “for uncomplicated urogenital gonorrhea, gepotidacin, which inhibits bacterial DNA replication, is noninferior to ceftriaxone plus azithromycin.” The study was “a phase 3 noninferiority study comparing oral gepotidacin (two 3,000-mg doses administered 10 to 12 hours apart) to 500 mg intramuscular ceftriaxone plus 1 g oral azithromycin for gonorrhea treatment.” The findings were published in The Lancet.